The human Nav1.5 F1486 deletion associated with long QT syndrome leads to impaired sodium channel inactivation and reduced lidocaine sensitivity

Journal of Physiology

Volumn 590, Issue 20, 2012, Pages 5123-5139

  Song, Weihua ^a   Xiao, Yucheng ^a   Chen, Hanying ^a   Ashpole, Nicole M ^a   Piekarz, Andrew D ^a   Ma, Peilin ^a   Hudmon, Andy ^a   Cummins, Theodore R ^a   Shou, Weinian ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIDOCAINE; PHENYLALANINE; SODIUM; SODIUM CHANNEL NAV1.5;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL FUNCTION; CELL MEMBRANE DEPOLARIZATION; CELL STRAIN HEK293; COMPUTER SIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE EXPRESSION SYSTEM; GENETIC ASSOCIATION; HEART MUSCLE CELL; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; INHIBITION KINETICS; INTRACELLULAR RECORDING; LONG QT SYNDROME; LOSS OF FUNCTION MUTATION; MATHEMATICAL MODEL; MOLECULAR PATHOLOGY; NEWBORN; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; QT PROLONGATION; RAT; SODIUM CURRENT; VOLTAGE CLAMP;

EID: 84867475069     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2012.235374     Document Type: Article

References (53)

1. Amin AS, Asghari-Roodsari A & Tan HL (2010). Cardiac sodium channelopathies. Pflugers Arch 460, 223-237.
2. + channels. Circ Res 79, 103-108.
3. Balser JR, Nuss HB, Orias DW, Johns DC, Marban E, Tomaselli GF & Lawrence JH (1996). Local anesthetics as effectors of allosteric gating. Lidocaine effects on inactivation-deficient rat skeletal muscle Na channels. J Clin Invest 98, 2874-2886.
4. Balser JR, Nuss HB, Romashko DN, Marban E & Tomaselli GF (1996). Functional consequences of lidocaine binding to slow-inactivated sodium channels. J Gen Physiol 107, 643-658.
5. Bankston JR, Yue M, Chung W, Spyres M, Pass RH, Silver E, Sampson KJ & Kass RS (2007). A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response. PLoS One 2, e1258.
6. + channels. Modification of block by alterations in the α-subunit III-IV interdomain. Circ Res 77, 584-592.
7. Bennett PB, Yazawa K, Makita N & George AL Jr (1995b). Molecular mechanism for an inherited cardiac arrhythmia. Nature 376, 683-685.
8. Butterworth JFt & Strichartz GR (1990). Molecular mechanisms of local anesthesia: a review. Anesthesiology 72, 711-734.
9. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P et al. (1998). Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392, 293-296.
10. Clancy CE, Tateyama M & Kass RS (2002). Insights into the molecular mechanisms of bradycardia-triggered arrhythmias in long QT-3 syndrome. J Clin Invest 110, 1251-1262.
11. Courtemanche M, Ramirez RJ & Nattel S (1998). Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. Am J Physiol Heart Circ Physiol 275, H301-H321.
12. Craelius W, Green WL & Harris DR (1990). Acute effects of thyroid hormone on sodium currents in neonatal myocytes. Biosci Rep 10, 309-315.
13. + channels. Am J Physiol Heart Circ Physiol 274, H477-H487.
14. Gaughan JP, Hefner CA & Houser SR (1998). Electrophysiological properties of neonatal rat ventricular myocytes with α1-adrenergic-induced hypertrophy. Am J Physiol Heart Circ Physiol 275, H577-H590.
15. Gellens ME, George AL Jr, Chen LQ, Chahine M, Horn R, Barchi RL & Kallen RG (1992). Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc Natl Acad Sci U S A 89, 554-558.
16. Grant AO, Chandra R, Keller C, Carboni M & Starmer CF (2000). Block of wild-type and inactivation-deficient cardiac sodium channels IFM/QQQ stably expressed in mammalian cells. Biophys J 79, 3019-3035.
17. Hanck DA, Nikitina E, McNulty MM, Fozzard HA, Lipkind GM & Sheets MF (2009). Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythmic drug affinity. Circ Res 105, 492-499.
18. Hedley PL, Jorgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, Corfield VA & Christiansen M (2009). The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat 30, 1486-1511.
19. Hille B (1977). Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol 69, 497-515.
20. Hille B (2001). Ion Channels of Excitable Membranes. Sinauer, Sunderland, MA.
21. Hines ML & Carnevale NT (1997). The NEURON simulation environment. Neural Comput 9, 1179-1209.
22. Jarecki BW, Piekarz AD, Jackson JO 2nd & Cummins TR (2010). Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents. J Clin Invest 120, 369-378.
23. Jarecki BW, Sheets PL, Jackson JO 2nd & Cummins TR (2008). Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation. J Physiol 586, 4137-4153.
24. Kass RS (2006). Sodium channel inactivation in heart: a novel role of the carboxy-terminal domain. J Cardiovasc Electrophysiol 17, S21-S25.
25. Kiyosue T & Arita M (1989). Late sodium current and its contribution to action potential configuration in guinea pig ventricular myocytes. Circ Res 64, 389-397.
26. Leffler A, Herzog RI, Dib-Hajj SD, Waxman SG & Cummins TR (2005). Pharmacological properties of neuronal TTX-resistant sodium channels and the role of a critical serine pore residue. Pflugers Arch 451, 454-463.
27. Luo CH & Rudy Y (1994). A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ Res 74, 1071-1096.
28. McNulty MM, Edgerton GB, Shah RD, Hanck DA, Fozzard HA & Lipkind GM (2007). Charge at the lidocaine binding site residue Phe-1759 affects permeation in human cardiac voltage-gated sodium channels. J Physiol 581, 741-755.
29. Makita N (2009). Phenotypic overlap of cardiac sodium channelopathies: individual-specific or mutation-specific? Circ J 73, 810-817.
30. Makiyama T, Akao M, Shizuta S, Doi T, Nishiyama K, Oka Y et al. (2008). A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. J Am Coll Cardiol 52, 1326-1334.
31. Meadows LS, Chen YH, Powell AJ, Clare JJ & Ragsdale DS (2002). Functional modulation of human brain Nav1.3 sodium channels, expressed in mammalian cells, by auxiliary β1, β2 and β3 subunits. Neuroscience 114, 745-753.
32. +-channel inactivation: charge neutralizations and deletions in the III-IV linker. Proc Natl Acad Sci U S A 89, 10905-10909.
33. + channels. Proc Natl Acad Sci U S A 93, 9270-9275.
34. Remme CA & Wilde AA (2008). SCN5A overlap syndromes: no end to disease complexity? Europace 10, 1253-1255.
35. Remme CA, Wilde AA & Bezzina CR (2008). Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations. Trends Cardiovasc Med 18, 78-87.
36. + channel isoform. Proc Natl Acad Sci U S A 86, 8170-8174.
37. Ruan Y, Denegri M, Liu N, Bachetti T, Seregni M, Morotti S, Severi S, Napolitano C & Priori SG (2010). Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3. Circ Res 106, 1374-1383.
38. Ruan Y, Liu N, Bloise R, Napolitano C & Priori SG (2007). Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 116, 1137-1144.
39. Saint DA, Ju YK & Gage PW (1992). A persistent sodium current in rat ventricular myocytes. J Physiol 453, 219-231.
40. Sheets MF, Fozzard HA, Lipkind GM & Hanck DA (2010). Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc Med 20, 16-21.
41. Sheets MF & Hanck DA (2007). Outward stabilization of the S4 segments in domains III and IV enhances lidocaine block of sodium channels. J Physiol 582, 317-334.
42. Song Y, Shryock JC & Belardinelli L (2008). An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol 294, H2031-H2039.
43. Stuhmer W, Conti F, Suzuki H, Wang XD, Noda M, Yahagi N, Kubo H & Numa S (1989). Structural parts involved in activation and inactivation of the sodium channel. Nature 339, 597-603.
44. Vassilev PM, Scheuer T & Catterall WA (1988). Identification of an intracellular peptide segment involved in sodium channel inactivation. Science 241, 1658-1661.
45. Volders PG, Vos MA, Szabo B, Sipido KR, de Groot SH, Gorgels AP, Wellens HJ & Lazzara R (2000). Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res 46, 376-392.
46. Wang DW, Desai RR, Crotti L, Arnestad M, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Rognum T, Schwartz PJ & George AL Jr (2007). Cardiac sodium channel dysfunction in sudden infant death syndrome. Circulation 115, 368-376.
47. + channel mutations in the congenital long QT syndrome. Proc Natl Acad Sci U S A 93, 13200-13205.
48. Wang DW, Yazawa K, Makita N, George AL Jr & Bennett PB (1997). Pharmacological targeting of long QT mutant sodium channels. J Clin Invest 99, 1714-1720.
49. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA & Keating MT (1995). SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80, 805-811.
50. + channels by local anesthetics in stably transfected mammalian cells: evidence for drug binding along the activation pathway. J Gen Physiol 124, 691-701.
51. +-channel inactivation. Proc Natl Acad Sci U S A 89, 10910-10914.
52. Wilde AA & Brugada R (2011). Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel. Circ Res 108, 884-897.
53. v1.5 in a neonate with fatal long QT syndrome. Int J Cardiol 145, 61-64.